Scynexis : FDA Approves Brexafemme As Oral Non-Azole Treatment For Vaginal Yeast Infections

Scynexis Inc. (SCYX) said that the U.S. Food and Drug Administration has approved Brexafemme or ibrexafungerp tablets, for oral use in patients with vulvovaginal candidiasis or VVC, also known as vaginal yeast infection.

Brexafemme was approved based on positive results from two Phase 3 studies in which oral ibrexafungerp demonstrated efficacy and a favorable tolerability profile in women with VVC.

Scynexis said it has partnered with Amplity Health, a global contract commercialization organization, to support U.S. commercialization of Brexafemme, with commercial launch scheduled in the second half of this year.

The company said it is working on completing its CANDLE study investigating ibrexafungerp for the prevention of recurrent VVC and expect we will be submitting a supplemental NDA in the first half of 2022.

Under Qualified Infectious Disease Product designation, Brexafemme is expected to receive ten years of market exclusivity in the U.S.: five years of new chemical entity exclusivity plus five additional years of exclusivity extension due to the QIDP designation.

Brexafemme is also protected by multiple patents, including a composition-of-matter patent covering the ibrexafungerp molecule. With patent term extension, this patent is expected to expire in 2035, providing 14 years of protection in the U.S.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Salt Lake City, Utah-based Huish Outdoors is recalling Oceanic Adult Dry Top Snorkels sold exclusively at Costco citing risk for drowning, U.S. Consumer Product Safety Commission said. The recall involves about 76,000 units of Oceanic Adult Dry Top Snorkels. The recall was initiated after Oceanic received 13 reports of the snorkels leaking. Boeing expects Europe's commercial aviation fleet to need 8,705 new airplanes through 2040 to cater to the growing leisure travel market in the region and fleet replacements with more fuel-efficient models, according to the Boeing's 2021 Commercial Market Outlook (CMO), an annual forecast of long-term demand for commercial airplanes and services. The U.S. Food and Drug Administration authorized marketing of a software developed by Paige.AI, a provider of AI-based digital diagnostics, which could help pathologists to identify prostate cancer. The software, called Paige Prostate, is the first and only artificial intelligence or AI-based pathology product to receive FDA approval for in vitro diagnostic or IVD use in detecting cancer...
Follow RTT